Medesis Pharma in France increases funding request for drugs against nuclear contamination


French President Emmanuel Macron, center, talks to a worker during his visit to Framatome, an international leader in nuclear energy, which designs, manufactures and installs fuel, instrumentation and control systems for nuclear power plants, in Le Creusot, France, December 8, 2020. Laurent Cipriani/Pool via REUTERS/File Photo

Join now for FREE unlimited access to


April 5 (Reuters) – French biotech company Medesis Pharma (ALMDP.PA) has applied for defense funding to accelerate the development of three drugs to treat nuclear contamination, it said on Tuesday, pushing its shares higher of nearly half their value at the start of the trade.

The company, whose shares rose 47%, said its products were relevant to the war in Ukraine, which increased the risk of nuclear war, as well as to European plans to increase nuclear production as the countries seek to reduce their dependence on Russian energy and secure low-carbon electricity.

“Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident”, specifies the group, announcing a request for funding from the French Defense Innovation Agency (DIA).

Join now for FREE unlimited access to


“To date, there is no treatment suitable for a serious nuclear accident,” he added in a statement.

The drug programs – which include a synthesized version of Prussian blue – are aimed at treating plutonium and cesium contamination, as well as preventing and treating respiratory and digestive inflammation caused by radiation.

President Emmanuel Macron, who is running for re-election this month, has announced plans for six new nuclear reactors and studies for eight others.

Sources told Reuters last week that the European Union had agreed to stockpile equipment and medicine to protect against nuclear incidents, after France called internal meetings for a bloc-wide plan to distribution of potassium iodide tablets. Read more

Join now for FREE unlimited access to


Reporting by Sarah Morland; edited by Barbara Lewis

Our standards: The Thomson Reuters Trust Principles.


About Author

Comments are closed.